Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
CMAJ
2022 Feb 22;1947:E242-E251. doi: 10.1503/cmaj.211698.
Show Gene links
Show Anatomy links
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
Ali K
,
Azher T
,
Baqi M
,
Binnie A
,
Borgia S
,
Carrier FM
,
Cavayas YA
,
Chagnon N
,
Cheng MP
,
Conly J
,
Costiniuk C
,
Daley P
,
Daneman N
,
Douglas J
,
Downey C
,
Duan E
,
Duceppe E
,
Durand M
,
English S
,
Farjou G
,
Fera E
,
Fontela P
,
Fowler R
,
Fralick M
,
Geagea A
,
Grant J
,
Harrison LB
,
Havey T
,
Hoang H
,
Kelly LE
,
Keynan Y
,
Khwaja K
,
Klein G
,
Klein M
,
Kolan C
,
Kronfli N
,
Lamontagne F
,
Lau R
,
Fralick M
,
Lee TC
,
Lee N
,
Lim R
,
Longo S
,
Lostun A
,
MacIntyre E
,
Malhamé I
,
Mangof K
,
McGuinty M
,
Mergler S
,
Munan MP
,
Murthy S
,
O'Neil C
,
Ovakim D
,
Papenburg J
,
Parhar K
,
Parvathy SN
,
Patel C
,
Perez-Patrigeon S
,
Pinto R
,
Rajakumaran S
,
Rishu A
,
Roba-Oshin M
,
Rushton M
,
Saleem M
,
Salvadori M
,
Scherr K
,
Schwartz K
,
Semret M
,
Silverman M
,
Singh A
,
Sligl W
,
Smith S
,
Somayaji R
,
Tan DHS
,
Tobin S
,
Todd M
,
Tran TV
,
Tremblay A
,
Tsang J
,
Turgeon A
,
Vakil E
,
Weatherald J
,
Yansouni C
,
Zarychanski R
,
Canadian Treatments for COVID-19 (CATCO)
,
Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group
.
???displayArticle.abstract???
BACKGROUND: The role of remdesivir in the treatment of patients in hospital with COVID-19 remains ill defined in a global context. The World Health Organization Solidarity randomized controlled trial (RCT) evaluated remdesivir in patients across many countries, with Canada enrolling patients using an expanded data collection format in the Canadian Treatments for COVID-19 (CATCO) trial. We report on the Canadian findings, with additional demographics, characteristics and clinical outcomes, to explore the potential for differential effects across different health care systems.
METHODS: We performed an open-label, pragmatic RCT in Canadian hospitals, in conjunction with the Solidarity trial. We randomized patients to 10 days of remdesivir (200 mg intravenously [IV] on day 0, followed by 100 mg IV daily), plus standard care, or standard care alone. The primary outcome was in-hospital mortality. Secondary outcomes included changes in clinical severity, oxygen- and ventilator-free days (at 28 d), incidence of new oxygen or mechanical ventilation use, duration of hospital stay, and adverse event rates. We performed a priori subgroup analyses according to duration of symptoms before enrolment, age, sex and severity of symptoms on presentation.
RESULTS: Across 52 Canadian hospitals, we randomized 1282 patients between Aug. 14, 2020, and Apr. 1, 2021, to remdesivir (n = 634) or standard of care (n = 648). Of these, 15 withdrew consent or were still in hospital, for a total sample of 1267 patients. Among patients assigned to receive remdesivir, in-hospital mortality was 18.7%, compared with 22.6% in the standard-of-care arm (relative risk [RR] 0.83 (95% confidence interval [CI] 0.67 to 1.03), and 60-day mortality was 24.8% and 28.2%, respectively (95% CI 0.72 to 1.07). For patients not mechanically ventilated at baseline, the need for mechanical ventilation was 8.0% in those assigned remdesivir, and 15.0% in those receiving standard of care (RR 0.53, 95% CI 0.38 to 0.75). Mean oxygen-free and ventilator-free days at day 28 were 15.9 (± standard deviation [SD] 10.5) and 21.4 (± SD 11.3) in those receiving remdesivir and 14.2 (± SD 11) and 19.5 (± SD 12.3) in those receiving standard of care (p = 0.006 and 0.007, respectively). There was no difference in safety events of new dialysis, change in creatinine, or new hepatic dysfunction between the 2 groups.
INTERPRETATION: Remdesivir, when compared with standard of care, has a modest but significant effect on outcomes important to patients and health systems, such as the need for mechanical ventilation. Trial registration: ClinicalTrials.gov, no. NCT04330690.
Ader,
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
2022, Pubmed
Ader,
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
2022,
Pubmed
Adhikari,
Critical care and the global burden of critical illness in adults.
2010,
Pubmed
Agarwal,
A living WHO guideline on drugs for covid-19.
2020,
Pubmed
Beigel,
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
2020,
Pubmed
Beigel,
Remdesivir for the Treatment of Covid-19 - Final Report.
2020,
Pubmed
Bhimraj,
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.
2020,
Pubmed
Donnelly,
Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System.
2021,
Pubmed
Estcourt,
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
2021,
Pubmed
Ford,
Pragmatic Trials.
2016,
Pubmed
French,
Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic - United States, July 2020-July 2021.
2021,
Pubmed
Goldman,
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
2020,
Pubmed
Horby,
Dexamethasone in Hospitalized Patients with Covid-19.
2021,
Pubmed
Lee,
Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis.
2021,
Pubmed
Lee,
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
2021,
Pubmed
Mahajan,
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study.
2021,
Pubmed
Murthy,
Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study.
2021,
Pubmed
Naylor,
Canadian federal-provincial/territorial funding of universal health care: fraught history, uncertain future.
2020,
Pubmed
Pan,
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
2021,
Pubmed
Rochwerg,
Remdesivir for severe covid-19: a clinical practice guideline.
2020,
Pubmed
Rubin,
Striving for Diversity in Research Studies.
2021,
Pubmed
Spinner,
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
2020,
Pubmed
Verma,
Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area.
2021,
Pubmed
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection,
A minimal common outcome measure set for COVID-19 clinical research.
2020,
Pubmed
Wang,
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
2020,
Pubmed
Wunsch,
Variation in critical care services across North America and Western Europe.
2008,
Pubmed
Yehya,
Reappraisal of Ventilator-Free Days in Critical Care Research.
2019,
Pubmed
Yusuf,
Interpreting Geographic Variations in Results of Randomized, Controlled Trials.
2016,
Pubmed